The company announced it had received marketing certification from Technischer Uberwachungs-Verein SUD Japan for NC-stat DPNCheck as a Class II Designated Controlled Medical Device based on the technical standards of the Japan Ministry of Health, Labor, and Welfare. NC-stat DPNCheck is a test designed to detect diabetic peripheral neuropathy, or DPN, at an early stage.
Omron Healthcare is the exclusive distributor for NeuroMetrix in Japan and will distribute NC-stat DPNCheck in the nation.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. The stock was up 26% to $2.37 at 12:19 p.m. More than 1.8 million shares had changed hands, which dwarfed the average volume of 62,722. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.